China Shineway Pharmaceutical GroupCSWYY 92 Net Current Asset Value is $24.77 as of Dec. 2025, which is 2073% above its 10-year median of 1.14. GuruFocus rates CSWYY with a GF Score™ of 92/100 and a GF Value™ of $17.28. The stock has 2 warning signs investors should review. Among 612 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks better than 95.59% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for China Shineway Pharmaceutical Group's Net Current Asset Value or its related term are showing as below:
CSWYY'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.77 Med: 1.14 Max: 1.9
Current: 0.77
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of China Shineway Pharmaceutical Group was 1.90. The lowest was 0.77. And the median was 1.14.
CSWYY's Price-to-Net-Current-Asset-Value is ranked better than 95.59% of 612
companies
in the Drug Manufacturers industry
Industry Median: 5.32
vs CSWYY: 0.77
China Shineway Pharmaceutical Group (OTCPK:CSWYY) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
China Shineway Pharmaceutical Group Net Current Asset Value Related Terms
China Shineway Pharmaceutical Group Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group Net Current Asset Value Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $24.77 mean?
China Shineway Pharmaceutical Group (CSWYY) has a Net Current Asset Value of $24.77 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on China Shineway Pharmaceutical Group and its competitors. This is 2073% above median its historical median of 1.14. Over the past decade, China Shineway Pharmaceutical Group's Net Current Asset Value has ranged from 0.77 to 1.90. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #27 out of 612 companies in the Drug Manufacturers industry, placing it in the top 4.4%.
Is China Shineway Pharmaceutical Group's Net Current Asset Value too high?
China Shineway Pharmaceutical Group's current Net Current Asset Value of $24.77 is 2073% above median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 1.90. The Drug Manufacturers industry median Net Current Asset Value is 5.32. China Shineway Pharmaceutical Group's value of $24.77 is 365.6% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #27 out of 612 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #27 out of 612 companies for Net Current Asset Value. This places China Shineway Pharmaceutical Group in the top 4% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 5.32. China Shineway Pharmaceutical Group's value of $24.77 is 365.6% above this benchmark. Historically, China Shineway Pharmaceutical Group's own Net Current Asset Value has ranged from 0.77 to 1.90 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 5.32, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.32, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Net Current Asset Value of $24.77 is 365.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Net Current Asset Value is $24.77, which is 2073% above median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current Net Current Asset Value of $24.77. The stock's GF Value™ is $17.28, compared to a current price of $19.25 — trading 11.4% above its estimated fair value. The current Net Current Asset Value is $24.77, which is 2073% above median its 10-year median of 1.14 and 365.6% above the Drug Manufacturers industry median of 5.32. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current Net Current Asset Value is $24.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 11.4% above its estimated GF Value™ of $17.28.
Key valuation signals for CSWYY:
Net Current Asset Value: $24.77 (2073% above median its 10-year median of 1.14)
GF Value™: $17.28 vs. price of $19.25 (11.4% above fair value)
Industry Position: 365.6% above the Drug Manufacturers median (#27 of 612)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
